Local Prescribing Information (Rheumatology):
Tocilizumab Injection IV and SC [Actemra®] - Actemra IV PI v13.0 dt. Feb 2021 Cipla | Actemra IV PI v13.0 dt. Feb 2021 Roche | Actemra SC PI v7.0 dt. Mar 2022 Cipla | Actemra SC PI v7.0 dt. Mar 2022 Roche
Rituximab Injection [Ristova® and Ikgdar®] - Ristova PI v12.0 dt. Jan 2021 | Ikgdar PI v12.0 dt. Jan 2021
Safety Update Information for Healthcare Professionals (Rheumatoid Arthritis):
Actemra® (Tocilizumab): A new Important Identified Risk: Hepatotoxicity
Disclaimer - Kindly note that it takes approximately up to 6 months to implement the revised PI in commercial stocks imported into India after submission to the health authorities. All PIs notified to or approved by the CDSCO are published on this website for all the HCPs prescribing Roche drugs within 10 calendar days.